Why a dead-clean sterile filter can pass pyrogen straight through
Bacterial endotoxin is a heat-stable lipopolysaccharide from the outer membrane of Gram-negative organisms. It survives sterilisation, passes a sterilising filter, and is…
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Purity
A shallow gradient resolves impurities that a steep one runs into the parent peak. Both methods are legitimate; only one of them can see the small stuff.
Gradient slope is where the reported number is really decided. Expressed properly, a gradient is a rate: percentage points of organic modifier per minute. A method taking forty minutes to move from twenty-five to forty-five per cent acetonitrile changes composition at half a point per minute, and it will resolve species that differ very slightly in hydrophobicity — including the deamidated and oxidised relatives of the parent. A twelve-minute method covering the same range moves at nearly two points per minute and will co-elute a good deal of that. The faster method is not incompetent. It is answering a coarser question.
A pump delivers a mixture of two solvents in a proportion that changes over time under program control. An autosampler injects a measured volume of dissolved sample into that stream. The stream passes through a column packed with particles bearing a bonded hydrophobic ligand, held in a thermostatted compartment. Analytes partition between the mobile phase and the stationary phase; as the organic fraction of the mobile phase rises, each species reaches a composition at which it prefers the mobile phase and leaves the column. A detector at the outlet measures ultraviolet absorbance continuously. Software records the signal and integrates it.
Peptides behave unusually within that framework, in a way worth knowing. Their retention is extremely sensitive to organic composition — much more so than small molecules — which means peptides do not so much elute gradually as leave the column over a narrow composition window. This is why isocratic separation of peptides is impractical and why gradient slope dominates the outcome. It is also why small changes to a gradient programme produce disproportionate changes in resolution.
Every element in the chain is a variable that a method disclosure would specify: column dimensions, particle and pore size, bonded phase, temperature, mobile-phase composition and additive, flow rate, gradient programme, injection volume and sample concentration, detection wavelength and bandwidth. Twelve numbers, all known to the analyst.1
Column choice sets the ceiling on what any gradient can achieve. Three parameters dominate. Particle size governs efficiency: reducing it narrows peaks, and the shift from five-micron to sub-two-micron packings over the past two decades is the reason a modern separation can resolve in ten minutes what once took forty, at the cost of much higher operating pressure and instruments built for it. Superficially porous or core-shell particles achieve much of the same benefit at moderate pressure by shortening the diffusion path.
Pore diameter governs access. The classical hundred-ångström pore was developed for small molecules and becomes restrictive as analyte size rises; for larger peptides a phase with pores in the region of three hundred ångströms allows the molecule to enter the particle and interact with the full bonded surface rather than only the exterior. Using a narrow-pore column for a large peptide produces broad, poorly shaped peaks that are frequently attributed to the sample.
Bonded phase chemistry governs selectivity. Octadecyl silica is the default and covers most peptide work; octyl phases retain less and can help with very hydrophobic sequences; phenyl and polar-embedded phases offer genuinely different selectivity and are therefore candidates for an orthogonal second method. Column dimensions matter too: at constant particle size a longer column gives more resolution and more pressure, and halving the internal diameter quarters the solvent consumption.2
Reversed-phase chromatography answers its own question superbly. The market asks it five questions and prints one answer.
Orla McCaffrey, Staff Writer, AnalyticsThe standard peptide mobile phase is water and acetonitrile with an acidic additive, and the choice of additive has consequences beyond pH. Trifluoroacetic acid at around a tenth of a per cent is the classical choice because it is an effective ion-pairing agent: it associates with basic residues, masks their charge, and produces markedly sharper and better-retained peaks than a simple pH adjustment achieves. For a difficult peptide separation the improvement is substantial.
It has two costs. Trifluoroacetate suppresses ionisation in electrospray mass spectrometry, which means a method optimised for chromatographic performance is frequently unsuitable for identity confirmation on the same run; formic acid is the usual compromise, giving worse peak shape and a usable mass spectrum. And residual trifluoroacetate from purification persists as a counter-ion, contributing mass to the vial and confounding content calculations, which is a manufacturing rather than an analytical issue but originates in the same chemistry.
Acetonitrile is preferred over methanol for peptide work on two grounds: lower viscosity, which means lower backpressure at a given flow, and lower ultraviolet absorbance at the short wavelengths peptide detection requires. Methanol’s absorbance in that region raises the baseline and degrades the signal-to-noise ratio exactly where the small impurity peaks are. A method reading at two hundred and fourteen nanometres in a methanol gradient is fighting its own solvent.
| Wavelength | Principal absorber | Sees fragments without aromatics | Baseline noise | Typical use |
|---|---|---|---|---|
| 214 nm | Amide bond | Yes | Higher | Peptide purity and related substances |
| 220 nm | Amide bond | Yes | Moderate | Peptide purity, quieter baseline |
| 254 nm | Aromatic systems | No | Low | Small-molecule work, legacy detectors |
| 280 nm | Trp, Tyr, Phe side chains | No | Low | Tracking an aromatic residue; not a purity method |
| Diode array, 200–400 nm | All of the above | Yes | Method-dependent | Peak purity assessment, spectral homogeneity |
| A purity figure generated at 280 nm is not comparable with one generated at 214 nm, and the difference is not a matter of a percentage point. Certificates reading at 280 nm circulate in this market; readers have sent us several. | ||||
A gradient should be quoted as a rate, not as a duration. Twenty-five to forty-five per cent acetonitrile over forty minutes is half a percentage point of organic per minute. The same range in twelve minutes is about one and two-thirds points per minute. That threefold difference in slope is the difference between resolving a deamidated relative from its parent and delivering both as one peak.
The underlying relationship is well established in peptide chromatography: resolution of closely related species improves as gradient slope decreases, up to the point where peak broadening from extended run times starts to give the gain back. Peak capacity — the number of peaks a method can theoretically resolve across its run — rises with shallower gradients and with more efficient columns, and it is the honest single-number summary of what a separation can do. It is never quoted in this trade.
The Journal’s standing request is simply that the gradient be printed. It is three numbers: starting composition, ending composition, time. Nobody regards it as commercially sensitive, every laboratory has it in the method file, and its presence converts a purity figure from an assertion into something comparable with the next certificate. Its absence is the reason two figures from two suppliers cannot be placed side by side, and that absence is a documentary decision rather than a technical constraint.3
Peptide separations are usually run with the column thermostatted somewhere between thirty and sixty degrees, and the temperature is doing more than stabilising retention times. Raising it lowers mobile-phase viscosity, which reduces backpressure and permits higher flow or smaller particles. It speeds mass transfer, narrowing peaks. And it changes selectivity, because the enthalpy of partitioning differs between species: two peaks that co-elute at thirty degrees may separate at fifty, and occasionally the reverse.
That last effect makes temperature a legitimate orthogonality lever, though a weaker one than changing pH or phase chemistry. It also makes it a source of irreproducibility when uncontrolled. A separation developed at ambient temperature in a cool laboratory and repeated in a warm one is not the same separation, and the retention-time drift that follows is frequently blamed on the column.
For peptides there is an additional consideration. Elevated temperature accelerates on-column degradation of labile sequences, and a peptide with an aspartate-proline bond held at sixty degrees in an acidic mobile phase for forty minutes may generate a fragment during the analysis. A purity figure obtained under such conditions includes a contribution the sample did not have when it was injected. This is not common and it is not hypothetical, and it is one reason method development for a labile peptide is not a matter of adopting a generic gradient.
Particle size determines efficiency but not selectivity. A column packed with 1.7-micron particles will produce sharper peaks and narrower bandwidths than a 5-micron equivalent, which means better resolution of closely spaced peaks, but both columns separate according to hydrophobicity and both will fail to resolve species that do not differ sufficiently in that property. Resolution—the separation of two peaks, measured by their distance relative to their width—is the joint product of efficiency and selectivity, and improvement in one does not compensate for inadequacy in the other.2
A peptide method development sequence therefore cannot stop at efficiency. Running a smaller particle after a failed separation is a rational experiment, but it is not the only experiment, and it is frequently not the right one. A shallower gradient, a different pH, a temperature shift or a stationary-phase change addresses selectivity directly, and a successful method development programme tests each before concluding that only a smaller particle will serve. The practical consequence is that method robustness and lifetime depend on whether the selectivity separation is known and defended, or whether the method relies on brute-force efficiency to hide a hidden selectivity problem.
Ruggedness testing in regulated pharmaceutical practice submits a method to deliberate small changes in conditions—temperature within a range, flow rate within a percentage, mobile-phase pH within a fraction, column lot change—and confirms that the method gives acceptably similar answers under all those conditions. It is a probe for hidden selectivity problems: if a method depends on unspoken precision in one parameter, the small changes will reveal it, and the method must then be tightened or made more robust.4 A method that survives ruggedness testing is one that works because of its design choices, not because of luck.
Ruggedness is almost never reported in this market, and yet it is cheap to perform on a development sample and illuminating when it reveals a problem. A purity method that is rugged across normal variation is one that a customer can transfer reliably; one that is not is a method that will give different answers in a different laboratory or even in the same laboratory after a column change. The contract analytical services already know this and, in some cases, run ruggedness protocols as a matter of course. Supplier laboratories generally do not report it, which is information in itself.
Readers who take one habit from this piece should take the second method. A single separation cannot detect its own co-elution, and a second run on a different principle costs instrument time on a sample already in the autosampler. Where two orthogonal figures agree, a purity claim has survived an attempt to break it. Where they disagree, the lower number is the one to write down.
Selected from correspondence received on this article. Writers are identified by initial, surname and city, verified before printing. Replies are from the desk that filed the piece or from the standards editor. Write to letters@compoundjournal.com.
Acting on your section about system suitability, I asked a laboratory whether the criteria had been met on my run. They sent the suitability summary the same afternoon, unprompted and without charge, and it showed a tailing factor of 1.3 and replicate agreement well inside a per cent. Nothing was being withheld. Nobody had ever asked.
— M. Sandhu, Amritsar
A small technical correction. You write that trifluoroacetic acid is used at around 0.1 per cent. In peptide work concentrations of 0.05 to 0.1 per cent are both common, and some methods run higher for particularly basic sequences. The figure reads as though it were a standard rather than a range.
— D. Chukwuma, Onitsha
Your table of what each method can see puts "only if resolved" against isoaspartate for RP-HPLC. That understates the difficulty. Resolving isoAsp from Asp routinely requires a method developed for the purpose, and on a generic gradient the two are frequently indistinguishable even at forty minutes.
— P. McAlinden, Belfast
Accepted, and the entry now reads that it requires a method developed for the purpose. Our original wording implied that a sufficiently shallow generic gradient would generally do it, which overstates what shallowness alone achieves.
Bacterial endotoxin is a heat-stable lipopolysaccharide from the outer membrane of Gram-negative organisms. It survives sterilisation, passes a sterilising filter, and is…
Aggregates dissociate in the mobile phase and are recorded as monomer. Only a size-based separation reports them.
Lot-level verification with a public report is a real and achievable thing. It exists in this market, on a minority of listings.
The Journal’s standing position: a mass that matches is necessary evidence of identity and nowhere near sufficient.
Where two methods disagree, the conservative convention is to report the lower figure. It is not universal, and whether a laboratory follows it belongs on the report.
The result is unremarkable. What the report omits is not.